Keyword: Fresenius Medical Care
Trump put forward an executive order to incentivize at-home kidney dialysis, potentially affecting thousands of people who undergo the procedure.
Dialysis giant Fresenius Medical Care announced plans to expand and elevate its North America-centric Frenova research subsidiary on the global stage.
Fresenius’ new global medical office will head up its work in clinical science and coordinate the company’s global network of clinics.
Fresenius dramatically widened its footprint in China, acquiring shares in multiple Chinese companies and hospital systems.
In the wake of Hurricane Michael, the two largest dialysis companies in the country have opened their doors to all patients seeking treatment.
Fresenius signed a $150 million global commercialization deal with Humacyte for its regenerative blood vessel implant and bought 19% of the company.
Vifor Pharma and Fresenius acquired a global license to commercialize Cara Therapeutics’ Korsuva for intense itching associated with CKD and dialysis.
The pharmacy chain will start a clinical trial later this year with a view to securing FDA approval and offering an at-home dialysis service by 2020.
Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.
The takeover will bolster Fresenius’ at-home dialysis unit, positioning it to profit if patients opt against receiving treatment in its care centers.